clinical trial · NCT06126497
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
Major Depressive DisorderRopanicant
brief summary
This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
started
Feb 5, 2024
primary completion
Jul 19, 2024
completion
Jul 19, 2024
last updated
Apr 8, 2026
detailed description
Approximately 36 participants will be randomly assigned to receive ropanicant either Dose 1 qd, Dose 2 bid, or Dose 3 mg bid for 2 weeks, in a ratio of 1:1:1 (12 participants in each treatment group). Following a screening period of up to 4 weeks, the participants will be treated for 2 weeks.
official title
An Open-Label Study Evaluating the Safety and Efficacy of Ropanicant in Participants With Moderate to Severe Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol